<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047250</url>
  </required_header>
  <id_info>
    <org_study_id>ML42606</org_study_id>
    <nct_id>NCT05047250</nct_id>
  </id_info>
  <brief_title>A Study of Atezolizumab Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase III, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, randomized study to evaluate the efficacy and safety of atezolizumab&#xD;
      compared with platinum-based chemotherapy consisting of a platinum agent (carboplatin or&#xD;
      cisplatin) in combination with pemetrexed (non-squamous disease) OR gemcitabine or paclitaxel&#xD;
      (squamous disease) in highly PD-L1 expressed, chemotherapy-naïve, EGFR/ALK wild type patients&#xD;
      with stage IV non-squamous or squamous NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) Assessed by Investigator</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 28 months)</time_frame>
    <description>Progression-free survival (PFS) assessed by investigator is defined as the time from randomization to the first occurrence of disease progression as determined by site investigator, according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS Assessed by IRF</measure>
    <time_frame>Randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 28 months)</time_frame>
    <description>PFS assessed by Independent Review Facility (IRF) is defined as the time from randomization to the first occurrence of disease progression as determined by IRF according to RECIST v1.1, or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Randomization to death from any cause (up to approximately 34 months)</time_frame>
    <description>Overall survival (OS) is defined as the time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS Rate Assessed by Investigators</measure>
    <time_frame>Randomization to 6-month</time_frame>
    <description>PFS rate assessed by Investigators at 6-month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS Rate Assessed by Investigators</measure>
    <time_frame>Randomization to 1-year</time_frame>
    <description>PFS rate assessed by Investigators at 1-year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS Rate Assessed by IRF</measure>
    <time_frame>Randomization to 6-month</time_frame>
    <description>PFS rate assessed by IRF at 6-month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS Rate Assessed by IRF</measure>
    <time_frame>Randomization to 1-year</time_frame>
    <description>PFS rate assessed by IRF at 1-year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rate at 1-Year</measure>
    <time_frame>Randomization to 1-year</time_frame>
    <description>OS rate at 1-year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rate at 2-Year</measure>
    <time_frame>Randomization to 2-year</time_frame>
    <description>OS rate at 2-year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Assessed by Investigators</measure>
    <time_frame>Randomization up to approximately 34 months</time_frame>
    <description>Objective response rate (ORR) is defined as the proportion of participants with a complete response (CR) or partial response (PR), as determined by investigators according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR Assessed by IRF</measure>
    <time_frame>Randomization up to approximately 34 months</time_frame>
    <description>ORR assessed by IRF according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Randomization up to approximately 34 months</time_frame>
    <description>Duration of response (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by investigators according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Randomization up to approximately 34 months</time_frame>
    <description>Percentage of participants with adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV infusion of atezolizumab on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin/Cisplatin+Pemetrexed (Non-Squaomous) or Gemcitabine/Paclitaxel (Squamous)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive platinum-based chemotherapy consisting of a platinum agent (carboplatin or cisplatin) in combination with pemetrexed (non-squamous disease) OR gemcitabine or paclitaxel (squamous disease).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed will be administered by IV infusion at a dose of 500 mg/m² on Day 1 of each 21-day cycle. Participants who do not experience disease progression per RECIST v1.1 after completing (four or six cycles of) induction treatment, will continue maintenance treatment with pemetrexed, given on Day 1 of each 21-day cycle until disease progression per RECIST v1.1.</description>
    <arm_group_label>Carboplatin/Cisplatin+Pemetrexed (Non-Squaomous) or Gemcitabine/Paclitaxel (Squamous)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be administered by IV infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine or paclitaxel.</description>
    <arm_group_label>Carboplatin/Cisplatin+Pemetrexed (Non-Squaomous) or Gemcitabine/Paclitaxel (Squamous)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin will be administered by IV infusion at a dose of 75 mg/m².</description>
    <arm_group_label>Carboplatin/Cisplatin+Pemetrexed (Non-Squaomous) or Gemcitabine/Paclitaxel (Squamous)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered by IV infusion at a dose of 1,250 mg/m² (in combination with cisplatin) or 1,000 mg/m² (in combination with carboplatin) on Days 1 and 8 of each 21-day cycle.</description>
    <arm_group_label>Carboplatin/Cisplatin+Pemetrexed (Non-Squaomous) or Gemcitabine/Paclitaxel (Squamous)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2 on Days 1 of each 21-day cycle.</description>
    <arm_group_label>Carboplatin/Cisplatin+Pemetrexed (Non-Squaomous) or Gemcitabine/Paclitaxel (Squamous)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC.&#xD;
&#xD;
          -  No prior treatment for Stage IV non-squamous or squamous NSCLC.&#xD;
&#xD;
          -  Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or&#xD;
             chemo-radiotherapy with curative intent for non-metastatic disease must have&#xD;
             experienced a treatment free interval of at least 6 months from randomization since&#xD;
             the last chemotherapy, radiotherapy, or chemo-radiotherapy cycle.&#xD;
&#xD;
          -  Tumor TC3 or IC3, as determined by SP142 performed by a central laboratory on&#xD;
             previously obtained archival tumor tissue or tissue obtained from a biopsy at&#xD;
             screening.&#xD;
&#xD;
          -  Measurable disease, as defined by RECIST v1.1.&#xD;
&#xD;
          -  Adequate hematologic and end-organ function.&#xD;
&#xD;
          -  Life expectancy ≥3 months.&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent or use&#xD;
             contraception, and agreement to refrain from donating.&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive methods, and agreement to refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known sensitizing mutation in the EGFR gene or ALK fusion oncogene.&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing CNS metastases.&#xD;
&#xD;
          -  Spinal cord compression not definitively treated with surgery and/or radiation, or&#xD;
             previously diagnosed and treated spinal cord compression without evidence that disease&#xD;
             has been clinically stable for ≥2 weeks prior to randomization.&#xD;
&#xD;
          -  Current leptomeningeal disease.&#xD;
&#xD;
          -  Uncontrolled tumor-related pain.&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures.&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia.&#xD;
&#xD;
          -  Malignancies other than NSCLC within 5 years prior to randomization, with the&#xD;
             exception of those with a negligible risk of metastasis or death treated with expected&#xD;
             curative outcome.&#xD;
&#xD;
          -  Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment&#xD;
             or within at least 5 months after the last dose of atezolizumab and 6 months for&#xD;
             chemotherapy.&#xD;
&#xD;
          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to biopharmaceuticals produced in Chinese hamster&#xD;
             ovary cells or any component of the atezolizumab formulation.&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency.&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest CT scan.&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) test result at screening.&#xD;
&#xD;
          -  Patients with active hepatitis B or active hepatitis C at screening.&#xD;
&#xD;
          -  Active tuberculosis.&#xD;
&#xD;
          -  Severe infections within 4 weeks prior to randomization, including, but not limited&#xD;
             to, hospitalization for complications of infection, bacteremia, or severe pneumonia.&#xD;
&#xD;
          -  Significant cardiovascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML42606 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences.</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chest Hospital; Oncology Department</name>
      <address>
        <city>Beijing</city>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha City</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital Of Central South University</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changzhou First People's Hospital</name>
      <address>
        <city>Changzhou</city>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu City</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daping Hospital of Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affilicated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou City</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital Zhejiang University</name>
      <address>
        <city>Hangzhou City</city>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Province Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Jinzhou Medical University</name>
      <address>
        <city>Jinzhou City</city>
        <zip>121001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linyishi Cancer Hospital</name>
      <address>
        <city>Linyi City</city>
        <zip>276034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linyi people's hospital</name>
      <address>
        <city>Linyi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Chest Hospital</name>
      <address>
        <city>Nanjing City</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing City</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Baiqiuen Hospital</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tumor Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <zip>430023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

